Search Results - "Burris, Howard A."

A phase I study of ATR inhibitor gartisertib (M4344) as a single agent and in combination with carboplatin in patients with advanced solid tumours.

Authors: Burris, Howard A. Berlin, Jordan Arkenau, Tobias et al.

Source: British Journal of Cancer. Apr2024, Vol. 130 Issue 7, p1131-1140. 10p.

Revolutionizing cancer drug development: Harnessing the potential of basket trials.

Authors: Subbiah, Vivek Burris, Howard A. Kurzrock, Razelle

Source: Cancer (0008543X). Jan2024, Vol. 130 Issue 2, p186-200. 15p.

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer.

Authors: Powles, Thomas Eder, Joseph Paul Petrylak, Daniel P. et al.

Source: Nature. 11/27/2014, Vol. 515 Issue 7528, p558-562. 5p.

Subjects: Metastasis, Bladder cancer treatment, Cancer chemotherapy, Somatic mutation, Antigens

An open-label phase I dose-escalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancer.

Authors: Liu, Joyce Burris, Howard Wang, Judy S. et al.

Source: Gynecologic Oncology. Dec2021, Vol. 163 Issue 3, p473-480. 8p.

Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer.

Authors: Burris, Howard A. Chan, Arlene Bardia, Aditya et al.

Source: British Journal of Cancer. Aug2021, Vol. 125 Issue 5, p679-686. 8p.

Phase II Study of Capecitabine in Combination With Thalidomide in Patients With Metastatic Breast Cancer.

Authors: Burris, Howard A. Jones, Suzanne F. Shipley, Dianna et al.

Source: Cancer Investigation. Jun2010, Vol. 28 Issue 4, p408-412. 5p. 3 Charts, 2 Graphs.

Erlotinib plus either pazopanib or placebo in patients with previously treated advanced non-small cell lung cancer: A randomized, placebo-controlled phase 2 trial with correlated serum proteomic signatures.

Authors: Spigel, David R. Burris, Howard A. Greco, F. Anthony et al.

Source: Cancer (0008543X). Jun2018, Vol. 124 Issue 11, p2355-2364. 10p.

TAK-228 (formerly MLN0128), an investigational dual TORC1/2 inhibitor plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies.

Authors: Burris, Howard Kurkjian, C. Hart, L. et al.

Source: Cancer Chemotherapy & Pharmacology. Aug2017, Vol. 80 Issue 2, p261-273. 13p.

A phase I dose escalation study of NK012, an SN-38 incorporating macromolecular polymeric micelle.

Authors: Burris, Howard Infante, Jeffrey Anthony Greco, F. et al.

Source: Cancer Chemotherapy & Pharmacology. May2016, Vol. 77 Issue 5, p1079-1086. 8p.

Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study.

Authors: Elimova, Elena Ajani, Jaffer Burris, Howard et al.

Source: Lancet Oncology. Jul2025, Vol. 26 Issue 7, p847-859. 13p.

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.

Authors: Rosenberg, Jonathan E. Hoffman-Censits, Jean Powles, Tom et al.

Source: Lancet. 5/7/2016, Vol. 387 Issue 10031, p1909-1920. 12p. 1 Diagram, 3 Charts, 2 Graphs.

Subjects: Transitional cell carcinoma, Disease progression, Cancer chemotherapy, Immunoglobulin G, Cellular immunity, Therapeutics

A phase I/II study of carfilzomib 2-10-min infusion in patients with advanced solid tumors.

Authors: Papadopoulos, Kyriakos Burris, Howard Gordon, Michael et al.

Source: Cancer Chemotherapy & Pharmacology. Oct2013, Vol. 72 Issue 4, p861-868. 8p.

Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial.

Authors: Burris, Howard A. Lebrun, Fabienne Rugo, Hope S. et al.

Source: Cancer (0008543X). May2013, Vol. 119 Issue 10, p1908-1915. 8p.

Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway.

Authors: Burris, Howard¹ howard.burris@scresearch.net

Source: Cancer Chemotherapy & Pharmacology. Apr2013, Vol. 71 Issue 4, p829-842. 14p.

Tanespimycin pharmacokinetics: a randomized dose-escalation crossover phase 1 study of two formulations.

Authors: Burris, Howard Berman, David Murthy, Bindu et al.

Source: Cancer Chemotherapy & Pharmacology. May2011, Vol. 67 Issue 5, p1045-1054. 10p.

Pharmacokinetic Study of Rucaparib in Patients With Advanced Solid Tumors.

Authors: Shapiro, Geoffrey I. Kristeleit, Rebecca S. Burris, Howard A. et al.

Source: Clinical Pharmacology in Drug Development. Jan2019, Vol. 8 Issue 1, p107-118. 12p.

AJS-1 Tumor-agnostic drug development: Ready for Prime Time.

Authors: Burris, Howard¹ (AUTHOR)

Source: Annals of Oncology. 2022 Supplement 6, Vol. 33, pS405-S405. 1p.

AJS-3 Incorporating AI into oncology practice: Opportunities and challenges.

Authors: Burris, Howard A.¹

Source: Annals of Oncology. 2021 Supplement 3, Vol. 32, pS232-S232. 1p.

A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors.

Authors: LoRusso, Patricia M. Infante, Jeffrey R. Kim, Kevin B. et al.

Source: BMC Cancer. 3/6/2017, Vol. 17, p1-13. 13p. 1 Diagram, 4 Charts, 1 Graph.

Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.

Authors: Hortobagyi, Gabriel N. Stemmer, Salomon M. Burris, Howard A. et al.

Source: New England Journal of Medicine. 3/10/2022, Vol. 386 Issue 10, p942-950. 9p.